Benserazide as a potential novel fetal hemoglobin inducer : an observational study in non-carriers of hemoglobin disorders
Copyright © 2020 Elsevier Inc. All rights reserved..
Induction of fetal hemoglobin production with hydroxyurea is an effective strategy in sickle cell disease and beta thalassemias, but up to 20% of patients do not respond to or cannot tolerate it. Benserazide is used in the treatment of Parkinson's disease and was noticed to induce gamma globin in preclinical models. We hypothesized that chronic treatment with benserazide-containing medication may be associated with increase in HbF production and in circulating F-cells. Blood samples were collected from 50 subjects including 35 patients on benserazide for Parkinson's disease, 10 healthy controls, and 5 patients with sickle cell anemia as positive controls for high fetal hemoglobin. We found a strong correlation between HbF and circulating F-cells in the entire population, but we found no significant increase in HbF and F-cell percentage in patients taking benserazide up to 700 mg daily. No hematologic abnormalities attributable to benserazide use after up to 22 years were detected. Our data support long-term safety and tolerability of benserazide at doses ten times higher than used in preclinical models to induce fetal hemoglobin. Further clinical trials enrolling patients with sickle cell disease and thalassemia are warranted to provide insight into its efficacy to treat those populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
|---|---|
| Enthalten in: |
Blood cells, molecules & diseases - 87(2021) vom: 15. März, Seite 102511 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Santos, Marina Erê Hummel Pimenta [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.07.2021 Date Revised 02.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bcmd.2020.102511 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317695835 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317695835 | ||
| 003 | DE-627 | ||
| 005 | 20231225163814.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bcmd.2020.102511 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317695835 | ||
| 035 | |a (NLM)33202326 | ||
| 035 | |a (PII)S1079-9796(20)30548-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Santos, Marina Erê Hummel Pimenta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Benserazide as a potential novel fetal hemoglobin inducer |b an observational study in non-carriers of hemoglobin disorders |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.07.2021 | ||
| 500 | |a Date Revised 02.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a Induction of fetal hemoglobin production with hydroxyurea is an effective strategy in sickle cell disease and beta thalassemias, but up to 20% of patients do not respond to or cannot tolerate it. Benserazide is used in the treatment of Parkinson's disease and was noticed to induce gamma globin in preclinical models. We hypothesized that chronic treatment with benserazide-containing medication may be associated with increase in HbF production and in circulating F-cells. Blood samples were collected from 50 subjects including 35 patients on benserazide for Parkinson's disease, 10 healthy controls, and 5 patients with sickle cell anemia as positive controls for high fetal hemoglobin. We found a strong correlation between HbF and circulating F-cells in the entire population, but we found no significant increase in HbF and F-cell percentage in patients taking benserazide up to 700 mg daily. No hematologic abnormalities attributable to benserazide use after up to 22 years were detected. Our data support long-term safety and tolerability of benserazide at doses ten times higher than used in preclinical models to induce fetal hemoglobin. Further clinical trials enrolling patients with sickle cell disease and thalassemia are warranted to provide insight into its efficacy to treat those populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Fetal hemoglobin | |
| 650 | 4 | |a Hydroxyurea | |
| 650 | 4 | |a Sickle cell disease | |
| 650 | 4 | |a Thalassemia | |
| 650 | 7 | |a Antiparkinson Agents |2 NLM | |
| 650 | 7 | |a Antisickling Agents |2 NLM | |
| 650 | 7 | |a Benserazide |2 NLM | |
| 650 | 7 | |a 762OS3ZEJU |2 NLM | |
| 650 | 7 | |a Fetal Hemoglobin |2 NLM | |
| 650 | 7 | |a 9034-63-3 |2 NLM | |
| 650 | 7 | |a Hydroxyurea |2 NLM | |
| 650 | 7 | |a X6Q56QN5QC |2 NLM | |
| 700 | 1 | |a Olops, Leticia |e verfasserin |4 aut | |
| 700 | 1 | |a Vendrame, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Tavares, Alvaro Henrique Junqueira |e verfasserin |4 aut | |
| 700 | 1 | |a Leonardo, Daniela Pinheiro |e verfasserin |4 aut | |
| 700 | 1 | |a de Azevedo, Paula Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Piovesana, Luiza Gonzaga |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Fernando Ferreira |e verfasserin |4 aut | |
| 700 | 1 | |a Fertrin, Kleber Yotsumoto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cells, molecules & diseases |d 1996 |g 87(2021) vom: 15. März, Seite 102511 |w (DE-627)NLM075208628 |x 1096-0961 |7 nnns |
| 773 | 1 | 8 | |g volume:87 |g year:2021 |g day:15 |g month:03 |g pages:102511 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bcmd.2020.102511 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 87 |j 2021 |b 15 |c 03 |h 102511 | ||